TY - JOUR
T1 - Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus
AU - Hogan, Andrew E.
AU - Gaoatswe, Gadintshware
AU - Lynch, Lydia
AU - Corrigan, Michelle A.
AU - Woods, Conor
AU - O'Connell, Jean
AU - O'Shea, Donal
PY - 2014/4
Y1 - 2014/4
N2 - Aims/hypothesis: Glucagon-like peptide 1 (GLP-1) is a gut hormone used in the treatment of type 2 diabetes mellitus. There is emerging evidence that GLP-1 has anti-inflammatory activity in humans, with murine studies suggesting an effect on macrophage polarisation. We hypothesised that GLP-1 analogue therapy in individuals with type 2 diabetes mellitus would affect the inflammatory macrophage molecule soluble CD163 (sCD163) and adipocytokine profile. Methods: We studied ten obese type 2 diabetes mellitus patients starting GLP-1 analogue therapy at a hospital-based diabetes service. We investigated levels of sCD163, TNF-α, IL-1β, IL-6, adiponectin and leptin by ELISA, before and after 8 weeks of GLP-1 analogue therapy. Results: GLP-1 analogue therapy reduced levels of the inflammatory macrophage activation molecule sCD163 (220 ng/ml vs 171 ng/ml, p<0.001). This occurred independent of changes in body weight, fructosamine and HbA1c. GLP-1 analogue therapy was associated with a decrease in levels of the inflammatory cytokines TNF-α (264 vs 149 pg/ml, p<0.05), IL-1β (2,919 vs 748 pg/ml, p<0.05) and IL-6 (1,379 vs 461 pg/ml p<0.05) and an increase in levels of the anti-inflammatory adipokine adiponectin (4,480 vs 6,290 pg/ml, p<0.002). Conclusions/interpretation: In individuals with type 2 diabetes mellitus, GLP-1 analogue therapy reduces the frequency of inflammatory macrophages. This effect is not dependent on the glycaemic or body weight effects of GLP-1.
AB - Aims/hypothesis: Glucagon-like peptide 1 (GLP-1) is a gut hormone used in the treatment of type 2 diabetes mellitus. There is emerging evidence that GLP-1 has anti-inflammatory activity in humans, with murine studies suggesting an effect on macrophage polarisation. We hypothesised that GLP-1 analogue therapy in individuals with type 2 diabetes mellitus would affect the inflammatory macrophage molecule soluble CD163 (sCD163) and adipocytokine profile. Methods: We studied ten obese type 2 diabetes mellitus patients starting GLP-1 analogue therapy at a hospital-based diabetes service. We investigated levels of sCD163, TNF-α, IL-1β, IL-6, adiponectin and leptin by ELISA, before and after 8 weeks of GLP-1 analogue therapy. Results: GLP-1 analogue therapy reduced levels of the inflammatory macrophage activation molecule sCD163 (220 ng/ml vs 171 ng/ml, p<0.001). This occurred independent of changes in body weight, fructosamine and HbA1c. GLP-1 analogue therapy was associated with a decrease in levels of the inflammatory cytokines TNF-α (264 vs 149 pg/ml, p<0.05), IL-1β (2,919 vs 748 pg/ml, p<0.05) and IL-6 (1,379 vs 461 pg/ml p<0.05) and an increase in levels of the anti-inflammatory adipokine adiponectin (4,480 vs 6,290 pg/ml, p<0.002). Conclusions/interpretation: In individuals with type 2 diabetes mellitus, GLP-1 analogue therapy reduces the frequency of inflammatory macrophages. This effect is not dependent on the glycaemic or body weight effects of GLP-1.
KW - GLP-1
KW - Inflammation
KW - Macrophage
KW - Obesity
UR - http://www.scopus.com/inward/record.url?scp=84896080822&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84896080822&partnerID=8YFLogxK
U2 - 10.1007/s00125-013-3145-0
DO - 10.1007/s00125-013-3145-0
M3 - Article
C2 - 24362727
AN - SCOPUS:84896080822
SN - 0012-186X
VL - 57
SP - 781
EP - 784
JO - Diabetologia
JF - Diabetologia
IS - 4
ER -